The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
RESEARCH ACCELERATION NETWORK GRANT AND RESEARCH ACCELERATION NETWORK-2 GRANT
The Pancreatic Cancer Action Network announced a bold initiative in February 2011, a vision of progress aimed at bettering the odds for everyone affected by pancreatic cancer: Double survival by the year 2020. Wage Hope is our rallying cry, our relentless call to action to accelerate progress in the fight against pancreatic cancer. We need you as our partners in this fight!
The Pancreatic Cancer Action Network has a competitive Grants Program that funds promising and meritorious research on pancreatic cancer. The organization’s grantmaking strategy recognizes the need to build the pipeline of researchers dedicated to studying pancreatic cancer and the urgency to accelerate scientific and medical breakthroughs that benefit patients. Early career grants are awarded to attract new researchers to the field of pancreatic cancer, and translational and clinical grants support research that is well poised for next steps and that has the potential to drive improvements in clinical practice and patient outcomes.
The adoption of the 2020 goal prompted an in-depth evaluation of the organization’s programs to ensure that they are effectively aligned with the goal. Since then, several new grant mechanisms have been introduced to speed discoveries that will contribute to the goal. In 2013, the Pancreatic Cancer Action Network launched the Research Acceleration Network (RAN) Grant, which provides $1 million over one to three years to support research that includes a clinical component designed to improve the detection or treatment of pancreatic cancer. Since then, seven promising multi-institutional projects have been funded by these grants.
In 2016, we will continue to offer RAN Grants and have expanded the eligibility criteria to include projects that deal with detection and treatment as well as prevention and supportive care. Based on our experiences with the RAN Grant and the pressing urgency to further speed improvements, we are pleased to introduce a new clinical research funding mechanism for 2016, the Research Acceleration Network (RAN)-2 Grant, which will support a more advanced project that is expected to have more immediate patient benefits. The RAN-2 Grant provides $2 million in funding for a Phase II treatment clinical trial or a robust nontherapeutic trial in pancreatic cancer. The grant term can range from one to three years.
Deadline: Jan. 15, 2016
Areas of Interest
- Option A: Research Acceleration Network (RAN) Grant provides $1 million in funding for research in pancreatic cancer that includes a clinical project with an endpoint that improves prevention, detection/diagnosis/ prognosis, treatment or supportive care. The grant term can range from one to three years, depending upon the project scope and milestones. The clinical component must be implemented no later than the beginning of the last year of the grant term. The project must involve at least two institutions and demonstrate strong potential to improve outcomes for pancreatic cancer patients. It is anticipated that two RAN Grants will be awarded.
- Option B: Research Acceleration Network (RAN)-2 Grant provides $2 million in funding over one to three years for research in pancreatic cancer that includes a Phase II treatment clinical trial or a robust prevention, detection/diagnosis/prognosis or supportive care trial implemented no later than the beginning of the second year of the grant term. At least two institutions must be involved in the project, and the impact on pancreatic cancer patients should be immediate, if not as soon as possible. Grant payments are triggered by proof of subject enrollment and trial participation. It is anticipated that one RAN-2 Grant will be awarded.
• One applicant, designated the contact principal investigator (contact PI), and at least one co-principal investigator (co-PI) from two distinct institutions are required.
• Additional co-PIs will be considered if their contribution is justified and adds a critical perspective to the project.
• Each PI must be an independent investigator and have a doctoral degree (including PhD, MD, DO, PharmD or equivalent) in the biomedical sciences or in a field applicable to health science research.
• The contact PI must be affiliated with an academic, medical or research institution within the United States.
• There are no citizenship requirements, but the contact PI who is not a U.S. citizen must have a visa status that provides sufficient time to complete the project and the grant term within the U.S.
• Co-PI(s) can be affiliated with any academic, medical or research institution in the world.
The RAN and RAN-2 Grants are designed to streamline and accelerate progress and effect the desired change in clinical outcome for pancreatic cancer by linking synergistic capabilities, creating an efficient management structure and providing funds that can be rapidly and strategically deployed. The basis for these grants is the recognition that there is high-potential research already underway that provides a strong foundation that can contribute to the 2020 goal of doubling survival for the disease. Funded projects will leverage existing knowledge and experience and be milestone- and timeline-driven. Each project will include metrics of success and measurable goals, and will represent a critical step in a longer-term effort that goes beyond the budget and timeframe of the grant. Plans for subsequent clinical studies and the feasibility of their completion will be presented. Clinical impact, validity, feasibility and, importantly, readiness are overriding evaluation criteria in selecting the projects to fund.
• The project team must have the expertise to lead all aspects of the proposed project, including a clinical trial.
• A researcher can be designated a contact PI on one application, either for a RAN or a RAN-2 Grant.
• Employees or subcontractors of a government or for-profit entity are not eligible to be a PI or to receive funds from the grant, but can be included as a collaborator or project investigator.
Funds from the RAN and RAN-2 Grants support project expenses over a one to three year period. Maximum funding is $1 million for a RAN Grant and $2 million for a RAN-2 Grant. The budget should be estimated for each year of the grant term, but will be regularly reviewed by the Steering Committee to allow for modifications in response to unanticipated and justified needs. There will be no carryover of funds beyond the grant term. Since this is an acceleration grant and the intent is to speed patient outcomes, investigators are urged to consider planning to complete the project in advance of a three-year end date, if realistic.